Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Anlotinib With PD-1 Inhibitor as Second Line Therapy in the Treatment of Metastatic Pancreatic Cancer

NCT05218629 is registered in ClinicalTrials.gov with Qingdao Central Hospital as lead sponsor.

NCT NCT05218629
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05218629 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Anlotinib With PD-1 Inhibitor as Second Line Therapy in the Treatment of Metastatic Pancreatic Cancer
Lead sponsor
Qingdao Central Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2022
Completion date
June 30, 2025
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

overall survival